SCHEMBL5780656

SCHEMBL5780656

FC(F)c1ccc2cc(Br)ccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.50
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
UGT2B7 P16662 1/20 0.38
BACE1 P56817 2/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
AHR P35869 2/20 0.34
NR4A2 P43354 1/20 0.34
NCEH1 Q6PIU2 1/20 0.34
TRPV4 Q9HBA0 1/20 0.33
KIF11 P52732 1/20 0.33
THRB P10828 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
NOS1 P29475 2/20 0.32
METAP2 P50579 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5779602 0.93 CYP2A6 (0.48) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL6816681 0.85 UGT2B7 (0.46) UGT2B7TRPV4KIF11CYP1A2CYP2C19
SCHEMBL2627116 0.82 CYP2A6 (0.56) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL27558953 0.80 CYP2A6 (0.48) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL24779222 0.78 UGT2B7 (0.64) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL30628955 0.78 UGT2B7 (0.64) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL13077231 0.78 KDM4E (0.48) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL6816249 0.78 UGT2B7 (0.44) CYP2A6MEN1KMT2AUGT2B7TRPV4
SCHEMBL29353067 0.77 CYP2A6 (0.77) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL192166 0.77 CYP2A6 (0.77) CYP2A6KDM4EMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017192304-A1 ARYLCARBOXAMIDES AND USES THEREOF INCEPTION 1, INC. (US) 2017-11-09 WO disclosed
CN-1312151-C (imidazol-1-yl-methyl)-pyridazine as NMDA receptor blocker HOFFMANN LA ROCHE (CH) 2007-04-25 CN disclosed
EP-1506190-B1 (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER HOFFMANN LA ROCHE (CH) 2006-06-14 EP disclosed
US-7005432-B2 Substituted imidazol-pyridazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-02-28 US disclosed
CN-1653062-A (imidazol-1-yl-methyl)-pyridazine as NMDA receptor blocker HOFFMANN LA ROCHE (CH) 2005-08-10 CN disclosed
EP-1506190-A1 (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER F. HOFFMANN-LA ROCHE AG (CH) 2005-02-16 EP disclosed
US-20030229096-A1 Substituted imidazol-pyridazine derivatives EVOTEC INTERNATIONAL GMBH (DE) 2003-12-11 US disclosed
WO-2003097637-A1 (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229096-A1 Substituted imidazol-pyridazine derivatives GRIN2B, GRIN2A, GRIN2C CYP2A6 3453/4885KDM4E 2754/4885MEN1 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.